Epigenomics AG Life Technologies to Supply Crucial Components for Second-Generation Colorectal Cancer Blood Test  
5/6/2011 9:21:29 AM

BERLIN & SEATTLE, Wash.--(BUSINESS WIRE)--Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnosis company, today announced the signing of a supply agreement with Life Technologies Corporation, a global provider of innovative life science solutions. As the Original Equipment Manufacturer (OEM) Life Technologies will supply its Dynabeads® MyOne™ SILANE and buffers for Epigenomics’ Epi proColon® 2.0 – the company’s second-generation colorectal cancer blood test that is in development for the European and U.S. in vitro diagnostic (IVD) market.